Edition:
United Kingdom

Spark Therapeutics Inc (ONCE.OQ)

ONCE.OQ on NASDAQ Stock Exchange Global Select Market

84.97USD
13 Jul 2018
Change (% chg)

$-4.30 (-4.82%)
Prev Close
$89.27
Open
$88.98
Day's High
$89.12
Day's Low
$83.69
Volume
148,831
Avg. Vol
206,117
52-wk High
$96.51
52-wk Low
$41.06

Chart for

About

Spark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a... (more)

Overall

Beta: --
Market Cap(Mil.): $3,132.52
Shares Outstanding(Mil.): 35.82
Dividend: --
Yield (%): --

Financials

  ONCE.OQ Industry Sector
P/E (TTM): -- 85.48 32.76
EPS (TTM): -6.38 -- --
ROI: -61.15 2.29 14.61
ROE: -63.88 3.86 16.34

BRIEF-Spark Therapeutics Reports Q1 Loss Per Share Of $1.25

* SPARK THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT BUSINESS PROGRESS

08 May 2018

BRIEF-Spark Therapeutics Says Entered Into Asset Purchase Agreement With Jazz Pharmaceuticals Ireland Ltd

* SPARK THERAPEUTICS SAYS ENTERED INTO ASSET PURCHASE AGREEMENT WITH JAZZ PHARMACEUTICALS IRELAND LIMITED - SEC FILING

30 Apr 2018

BRIEF-Children's Hospital Of Philadelphia Foundation To Engage In Dialogue With Spark Therapeutics To Be Allowed To Designate At Least 1 Board Member

* CHILDREN'S HOSPITAL OF PHILADELPHIA FOUNDATION - TO ENGAGE IN DIALOGUE WITH SPARK THERAPEUTICS TO BE ALLOWED TO DESIGNATE AT LEAST 1 BOARD MEMBER

09 Mar 2018

BRIEF-Spark Therapeutics Reports Cash And Cash Equivalents And Marketable Securities Of $540.2 Mln As Of Dec. 31, 2017

* SPARK THERAPEUTICS REPORTS 2017 FINANCIAL RESULTS AND RECENT BUSINESS PROGRESS

20 Feb 2018

Spark licenses blindness gene therapy rights outside U.S. to Novartis

Spark Therapeutics Inc, whose breakthrough gene therapy to treat a rare form of blindness was approved by U.S. regulators in December, said on Wednesday that it had licensed rights to the drug outside the United States to Switzerland-based Novartis AG.

25 Jan 2018

UPDATE 1-Spark licenses blindness gene therapy rights outside U.S. to Novartis

Jan 24 Spark Therapeutics Inc, whose breakthrough gene therapy to treat a rare form of blindness was approved by U.S. regulators in December, said on Wednesday that it had licensed rights to the drug outside the United States to Switzerland-based Novartis AG.

25 Jan 2018

Spark licenses blindness gene therapy rights outside U.S. to Novartis

Jan 24 Spark Therapeutics Inc, whose breakthrough gene therapy to treat a rare form of blindness was approved by U.S. regulators in December, has licensed rights to the drug in markets outside the United States to Switzerland-based Novartis AG, it said on Wednesday.

24 Jan 2018

BRIEF-Spark Therapeutics Enters Into Licensing, Supply Agreement For Investigational Voretigene Neparvovec Outside U.S.

* SPARK THERAPEUTICS ENTERS INTO A LICENSING AND SUPPLY AGREEMENT FOR INVESTIGATIONAL VORETIGENE NEPARVOVEC OUTSIDE THE U.S.

24 Jan 2018

Earnings vs. Estimates